Patients with high-risk AML ineligible for allogeneic hematopoietic stem cell transplantation (allo-SCT) have poor outcomes and low likelihood of cure 1 . Maintenance cytotoxic chemotherapy in AML has consistently failed to show a benefit 2 . Recent data suggest that there may be a role for hypomethylating agents (HMAs) as maintenance therapy in older individuals with AML 3 , 4 .
No takes yet. Share an insight, caveat, or question.
Reville et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: